

SEQUANA MEDICAL NV

ISIN: BE0974340722 WKN: - Asset Class: **Stock**

Company

2024/06/28 17:35:17

Price

1.40 EUR

Difference ▲ 0.72%(0.01)

sequanamedical



Contact Details

SEQUANA MEDICAL NV
--
Kortrijksesteenweg 1112,
Sint-Denijs-Westrem
9051 Ghent

Tel: +32-9-298-28-28
Fax: +
Web: <http://www.sequanamedical.com>
E-mail: -

Company Profile

Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company focuses on the treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. It offers alfapump, an implantable, programmable, wirelessly-charged, battery-powered system that manages refractory ascites and malignant ascites. The company was founded by Noel L. Johnson in 2006 and is headquartered in Ghent, Belgium.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	6,296,000		23,089,000		12,890,000	
Common stock capital		2,926,000		2,460,000		1,924,000
Fixed assets	3,804,000		2,935,000		1,814,000	
Equity capital of a company		-19,465,000		-2,153,000		-786,000
Cash and cash equivalents	2,584,000		18,874,000		9,600,000	
Accrued liabilities		667,000		228,000		509,000
Other assets	-		-		-	
Current liabilities		19,465,000		15,148,000		7,180,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		10,100,000		13,030,000		8,311,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	10,101,000	10,101,000	26,025,000	26,025,000	14,705,000	14,705,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	70	60
Equity ratio	-192.70%	-8.27%	-5.35%
Debt-equity ratio	-151.89%	-1,308.65%	-1,968.71%

Others

	2023	2022	2021
Tax Expense Rate	0.49%	0.40%	-1.69%

SEQUANA MEDICAL NV

ISIN: BE0974340722 WKN: - Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	712,000	922,000	370,000
Net income	-32,563,000	-30,763,000	-23,615,000
EBIT	-30,736,913	-30,006,851	-22,649,394
Operating income before taxes	-32,725,000	-30,886,000	-23,221,000
Cash Flow	-29,992,000	-27,796,000	-23,617,000
Net interest income	-1,988,000	-879,000	-572,000
Research and development expenses	5,277,000	7,706,000	6,140,000
Income taxes	-161,000	-123,000	393,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	-	13,181	6,175

Board of Directors

Pierre Hubert Andre Chauvineau	Chairman of Supervisory Board
Ken MacLeod	Member of Supervisory Board
Rudy Dekeyser	Member of Supervisory Board
Alexandra Clyde	Member of Supervisory Board
Douglas Kohrs	Member of Supervisory Board
Ids van der Weij	Member of Supervisory Board
Jacqueline Fielding	Member of Supervisory Board
Wim Ottevaere	Member of Supervisory Board

Members of Management Board

Ian Crosbie	Chairman of Managing Board
Andreas Wirth	Member of Executive Committee
Dragomir Latic	Member of Executive Committee
Gijs Klarenbeek	Member of Executive Committee
Kirsten Van Bockstaele	Member of Executive Committee
Martijn Blom	Member of Executive Committee
Oliver Gódje	Member of Executive Committee
Timur Resch	Member of Executive Committee